Summary
With the objective of establishing the optimal therapy for minimally differentiated acute myeloid leukemia (AML-M0), we examined the therapeutic results of five AML-M0 cases and reviewed the literature. In a series of 63 patients with newly diagnosed acute leukemia who were admitted to the Main Hospital of Nippon Medical School, five patients fit the criteria for AML-M0: negative myeloperoxidase (MPO) and Sudan black B reaction by light microscopy, negative for B- and T-lineage markers, and positive for myeloid markers. They were treated by means of AdVP [adriamycin, vincristine, and prednisolone (PSL)] therapy and/or BHAC-DMP [behenoylcytosine arabinoside (BHAC), daunorubicin (DNR), 6-mercaptopurine (6-MP), and PSL] therapy. The AdVP therapy was unsuccessful in the two patients who received it, while a complete remission (CR) was achieved with the BHAC-DMP therapy in three of four patients. Although one patient treated with BHAC-DMP did not achieve CR, his blasts were apparently sensitive to the therapy. In assessable cases in the literature where leukemic blasts were MPO-negative, myeloid marker-positive and B- and T-lineage marker-negative, CR was achieved in 54.5% and 44.4% with anti-acute myeloid leukemia therapy and anti-acute lymphocytic leukemia therapy, respectively. Five cases in the literature were treated with a chemotherapeutic regimen containing BHAC [or cytosine arabinoside (Ara-C)], DNR, and 6-MP, and all achieved CR. The regimen containing BHAC (or Ara-C), DNR, and 6-MP may be useful as induction chemotherapy for AML-MO.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asou N, Suzushima H, Hattori T, Nishikawa K, Wang JX, Okubo T, Oura K, Sato M, Kawano F, Shido T, Takatsuki K (1991) Acute unclassified leukemia originating from undifferentiated cells with the aberrant rearrangement and expression of immunoglobulin and T-cell receptor genes. Leukemia 5: 293–299
Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Tarek Elghetany M, Allen SL, Rai K, Lee EJ, Schiffer CA, Bloomfield CD (1991) Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77: 2242–2250
Bassan R, Biondi A, Benvestito S, Tini ML, Abbate M, Viero P, Barbui T, Rambaldi A (1992) Acute undifferentiated leukemia with CD 7 and CD 13 immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer 69: 396–404
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 78: 325–329
Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D (1989) Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 72: 161–166
Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R (1991) A classification of acute leukaemia for the 1990s. Ann Hematol 62: 16–21
Graham RC, Karnovsky MJ (1966) The early stages of absorption of injected horse-radish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem 14: 291–302
Grand R, Vannier JP, Bene MC, Faure GC, Bernard A (1989) Correlations between acute lymphoid leukemia (ALL) immunophenotype and clinical and laboratory data at presentation, a study of 350 patients. Cancer 64: 1437–1446
Inokuchi K, Komiya I, Dan K, Kuriya S, Sinohara T, Nomura T (1990) TdT-positive, SmIg-negative B precursor cell leukemia with Burkitt morphology: a case report. Leukemia Lymphoma 2: 251–255
Kantarjian HM, Hirsch-Ginsberg C, Yee G, Huh Y, Freireich E, Stass S (1990) Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood 76: 808–813
Kita K, Nasu K, Kamesaki H, Doi S, Tezuka H, Tatsumi E, Fukuhara S, Nishikori M, Uchino H, Shirakawa S (1985) Phenotypic analysis of acute lymphoblastic leukemia (ALL) cells which are classified as non-T non-B and negative for common ALL antigen. Blood 66: 47–52
Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA (1987) Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood 70: 1400–1406
Lo Coco F, Pasqualetti D, Lopez M, Panzini E, Gentile A, Latagliata R, Monarca B, De Rossi G (1989) Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers. Blut 58: 235–240
Lo Coco F, De Rossi G, Pasqualetti D, Lopez M, Diverio D, Latagliata R, Fenu S, Mandelli F (1989) CD7-positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Haematol 73: 480–485
Matutes E, Pombo de Oliveira M, Foroni L, Morilla R, Catovsky D (1988) The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia. Br J Haematol 69: 205–211
Nguyen D, Brynes RK, Macaulay L, Kaplan B, Pinter-Brown LC (1989) Acute myeloid leukemia, FAB M-1 microgranular variant: a multiparameter study. Hematol Pathol 3: 11–22
Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–877
Parreira A, Pombo de Oliveira MS, Matutes E, Foroni L, Morilla R, Catovsky D (1988) Terminal deoxynucleotidyl transferase-positive acute myeloid leukaemia: an association with immature myeloblastic leukaemia. Br J Haematol 69: 219–224
Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD (1987) Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 316: 1111–1117
Urbano-Ispizua A, Matutes E, Villamor N, Ribera JM, Feliu E, Montserrat E, Grañena A, Vives-Corrons JL, Rozman C (1990) Clinical significance of the presence of myeloidassociated antigens in acute lymphoblastic leukaemia. Br J Haematol 75: 202–207
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yokose, N., Ogata, K., Ito, T. et al. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). Ann Hematol 66, 67–70 (1993). https://doi.org/10.1007/BF01695886
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01695886